Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 3/20 | 0.47 |
| ▸ | PTPRB | P23467 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25794159 | 0.87 | USP30 (0.52) | USP30GPR119PTPN2PTPN1PTPN6 | |
| SCHEMBL31758616 | 0.87 | USP30 (0.52) | USP30GPR119HPGDKMT2AMEN1 | |
| SCHEMBL69078 | 0.86 | GPR119 (0.51) | USP30GPR119KMT2AKDM4EPKM | |
| SCHEMBL3171496 | 0.85 | USP30 (0.46) | USP30GPR119PTPN2PTPN1PTPN6 | |
| SCHEMBL3182755 | 0.84 | PDK2 (0.47) | USP30GPR119PTPN2PTPN1PTPN6 | |
| SCHEMBL25794457 | 0.84 | USP30 (0.49) | USP30GPR119PTPN2PTPN1PTPN6 | |
| SCHEMBL19540938 | 0.83 | USP30 (0.57) | USP30GPR119PTPN2PTPN1PTPN6 | |
| SCHEMBL3179424 | 0.83 | NPC1 (0.51) | USP30GPR119PTPN2PTPN1PTPN6 | |
| SCHEMBL3186914 | 0.83 | PDK2 (0.56) | USP30GPR119PTPN2PTPN1PTPN6 | |
| SCHEMBL3182707 | 0.83 | PTPRB (0.60) | USP30GPR119PTPN2PTPN1PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008760-A1 | DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED | 2026-01-08 | — | — | US | disclosed |
| EP-2522669-A1 | 3-Spirocyclic indolyl derivatives useful as ORL-1 receptor modulators | Janssen Pharmaceutica NV (BE) | 2012-11-14 | — | — | EP | disclosed |
| US-7655670-B2 | 1-((tetrahydropyran-2-yl)oxy-ethyl)-5-tert-butoxycarbonyl-spiro[indoline-3,4'-piperidin]-2-one; ORL-1 (orphan opioid receptor) G-protein coupled receptor; brain, psychological disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-02 | — | — | US | disclosed |
| US-7655670-B2 | 1-((tetrahydropyran-2-yl)oxy-ethyl)-5-tert-butoxycarbonyl-spiro[indoline-3,4'-piperidin]-2-one; ORL-1 (orphan opioid receptor) G-protein coupled receptor; brain, psychological disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-02 | — | — | US | disclosed |
| US-7655670-B2 | 1-((tetrahydropyran-2-yl)oxy-ethyl)-5-tert-butoxycarbonyl-spiro[indoline-3,4'-piperidin]-2-one; ORL-1 (orphan opioid receptor) G-protein coupled receptor; brain, psychological disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-02 | — | — | US | disclosed |
| US-20070112016-A1 | Novel 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-17 | — | — | US | disclosed |
| US-20070112016-A1 | Novel 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-17 | — | — | US | disclosed |
| US-20070112016-A1 | Novel 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112016-A1 | Novel 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators | OXER1, OGFRL1, NR1H2 | USP30 3051/4885GPR119 18/4885PTPN2 1506/4885 |
| US-20260008760-A1 | DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | DPP9, DPP7, DPP4 | USP30 2001/4885GPR119 127/4885PTPN2 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.